Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2024-04-12 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞董事会审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm PwC Zhongtian for the 2023 fiscal year audit. It details the qualifications of the accounting firm, the procedures for hiring the auditor, and the audit committee's oversight activities. The content focuses on the audit process and the committee's evaluation of the auditor's performance, which aligns with the definition of an Audit Report / Information (AR). The document is not a full annual report, nor is it an announcement or certification. It contains substantive information about the audit oversight, making it an audit-related report rather than a simple announcement or regulatory filing. FY 2023
2024-04-12 Chinese
关于神州细胞非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report issued by PwC (普华永道中天会计师事务所) concerning non-operating fund occupation and other related party fund transactions for Beijing Shenzhou Cell Biotechnology Group Co., Ltd. for the fiscal year ending December 31, 2023. It references a limited assurance engagement on a summary table of related party fund occupation and transactions, prepared according to regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange. The document includes detailed financial data and audit conclusions, indicating it is a standalone audit report focused on a specific issue rather than a full annual report or interim report. It is not a mere announcement or certification but contains substantive audit findings and financial data. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2023
2024-04-12 Chinese
神州细胞2024年度“提质增效重回报”行动方案
Management Reports Classification · 95% confidence The document is a detailed action plan for the year 2024 by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It outlines the company's strategic initiatives, operational goals, R&D plans, governance improvements, and investor relations activities. It includes financial performance data for 2023 and projections for 2024, but it is not a formal financial report like an annual or interim report. It is not an earnings release or a regulatory filing announcing a report. The document focuses on management's plans and explanations about business trends, operational improvements, and outlook, which aligns with the definition of a Management Report (MDA). The length and detail confirm it is a substantive report rather than a brief announcement or presentation. Therefore, the best classification is Management Reports (MDA).
2024-04-12 Chinese
神州细胞2023年年度股东大会通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2023 Annual General Meeting (AGM) of Beijing Sinocell Biotechnology Group Co., Ltd. It includes details such as the date, voting methods, meeting agenda, and instructions for shareholders to attend and vote. It does not contain the actual annual report or financial statements but rather the announcement and procedural information for the AGM. The document length is 3628 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2024-04-12 Chinese
神州细胞2023年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制评价报告' which translates to '2023 Annual Internal Control Evaluation Report'. It is issued by the company's board and management, discussing the effectiveness of internal controls over financial reporting and other operational controls as of December 31, 2023. The content includes detailed evaluation criteria, conclusions on control effectiveness, and descriptions of control deficiencies and remediation status. It is a comprehensive report on internal control evaluation rather than a brief announcement or certification. The document length is 4071 characters, which is relatively short but contains substantive content and detailed evaluation results, not just a notice or link to a report. This type of report is typically classified as an Audit Report / Information (AR) because it focuses on internal control evaluation and audit opinions related to financial reporting controls, rather than a full Annual Report (10-K) or Interim Report (IR). It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains the full evaluation content, not just a notice. Therefore, the best fitting category is AR (Audit Report / Information). FY 2023
2024-04-12 Chinese
神州细胞2023年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '2023年度财务报表及审计报告' which translates to '2023 Annual Financial Statements and Audit Report'. It contains detailed financial statements including consolidated and company balance sheets, profit and loss statements, cash flow statements, changes in equity, and extensive notes to the financial statements. It also includes a comprehensive audit report by PwC (普华永道), with audit opinions, key audit matters, management responsibilities, and auditor responsibilities. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content clearly matches the definition of an Audit Report / Information (AR) as it is a standalone audit report with applied accounting principles and audit results, separate from a full annual report. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-12 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.